医学
免疫疗法
宫颈癌
靶向治疗
肿瘤科
癌症
内科学
癌症免疫疗法
作者
Gulden Menderes,Jonathan Black,Carlton L. Schwab,Alessandro D. Santin
标识
DOI:10.1586/14737140.2016.1121108
摘要
The prognosis of patients with metastatic cervical cancer is poor with a median survival of 8–13 months. Despite the potency of chemotherapeutic drugs, this treatment is rarely curative and should be considered palliative only. In the last few years, a better understanding of Human papillomavirus tumor-host immune system interactions and the development of new therapeutics targeting immune check points have renewed interest in the use of immunotherapy in cervical cancer patients. Moreover, next generation sequencing has emerged as an attractive option for the identification of actionable driver mutations and other markers. In this review, we provide background information on the molecular biology of cervical cancer and summarize immunotherapy studies, targeted therapies, including those with angiogenesis inhibitors and tyrosine kinase inhibitors recently completed or currently on-going in cervical cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI